GlassScriptPhysician profile
Jenna Baer
NPI 1932979317
$645.52
in general payments reported to CMS, 2019-2025
17 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $165.37 | 2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $114.29 | 2025 | |
| Exact Sciences Corporation | $49.84 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $49.11 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $35.66 | 2025 | |
| Lundbeck LLC | $32.53 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $30.67 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $22.96 | 2025 | Veozah |
| Lilly USA, LLC | $21.00 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2025 | Relistor |
| Otsuka America Pharmaceutical, INC. | $19.85 | 2025 | Rexulti |
| Dexcom, INC. | $19.80 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.66 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2025 | Jardiance |
| Ardelyx, INC. | $14.80 | 2025 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.56 | 2025 | |
| Phathom Pharmaceuticals, INC. | $3.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Baer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.